Biotechnology company developing gene therapies for cancer treatment and respiratory diseases.
Genprex, Inc., headquartered in Austin, Texas, is a clinical-stage biotechnology firm specializing in gene therapy. Established in 2009, the company is dedicated to advancing innovative treatments primarily for cancer and diabetes patients. At the forefront of its pipeline is REQORSA (GPX-001), the lead product candidate designed to address both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Genprex is also actively developing GPX-002, a promising gene therapy in its preclinical stages, aimed at combating diabetes.
REQORSA (GPX-001) represents Genprex's flagship therapeutic approach, leveraging gene therapy to potentially revolutionize lung cancer treatment. The company's strategic focus extends beyond oncology, with GPX-002 targeting diabetes, underscoring its commitment to addressing significant medical needs through innovative genetic interventions. With a robust research and development agenda, Genprex continues to strengthen its position in the biotechnology sector, poised to deliver impactful therapies that could redefine patient care.
Genprex, Inc. operates with a vision to harness the transformative potential of gene therapy in combating complex diseases. Supported by a dedicated team of researchers and industry experts, the company remains steadfast in its mission to advance novel treatment options that offer new hope for patients facing challenging medical conditions. Through its cutting-edge approach and strategic initiatives, Genprex aims to contribute significantly to the evolving landscape of genetic medicine, striving to improve outcomes and quality of life for individuals worldwide.